Role of natural killer cells in liver transplantation treatment of liver cancer.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28962171)

Published in Exp Ther Med on July 09, 2017

Authors

Wenbin Ji1, Jin Chen1, Yuche Mi1, Guiliang Wang1, Xinjiang Xu1, Weizheng Wang2

Author Affiliations

1: Department of Radiology, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, P.R. China.
2: Department of Vascular Surgery, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, P.R. China.

Articles cited by this

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46

The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28

Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09

The global burden of cancer: priorities for prevention. Carcinogenesis (2009) 3.73

Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01

OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant (2013) 1.48

Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology (2010) 1.39

The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation (1990) 1.21

Regulation of hepatocyte fate by interferon-γ. Cytokine Growth Factor Rev (2011) 1.13

Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol (2009) 0.97

Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine (2012) 0.91

NK cells and interferons. Cytokine Growth Factor Rev (2014) 0.90

Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc (2010) 0.89

Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc (2011) 0.85

Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel) (2015) 0.84

Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection. Clin Exp Immunol (2015) 0.83

Current challenges in liver transplantation for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol (2014) 0.83

Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int (2009) 0.82

Pretransplantation tumor necrosis factor-alpha production predicts acute rejection after liver transplantation. Liver Transpl (2000) 0.81

Markers of acute rejection and graft acceptance in liver transplantation. World J Gastroenterol (2015) 0.81

Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transpl Immunol (2014) 0.81

Liver transplantation: a systematic review of long-term quality of life. Liver Int (2014) 0.81

Monitoring serial CD4⁺ T-cell function after liver transplantation can be used to predict hepatocellular carcinoma recurrence. Transplant Proc (2015) 0.79

[International registry of liver tumors in liver transplantation. A registry update on hepatocellular carcinoma (HCC)]. Zentralbl Chir (2000) 0.79

Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and pim-3-silencing effects. Mol Cancer Ther (2014) 0.77

Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. Transpl Int (2012) 0.77

Evolution of CD4⁺CD25(hi) T cell subsets in Aspergillus-infected liver transplantation recipients reduces the incidence of transplantation rejection via upregulating the production of anti-inflammatory cytokines. Genet Mol Res (2014) 0.77

Comparison of short- and long-term outcomes after early versus late liver retransplantation: a single-center experience. J Surg Res (2013) 0.77

Expectations from imaging for pre-transplant evaluation of living donor liver transplantation. World J Radiol (2014) 0.75